Vistagen Therapeutics Inc (VTGN) Stock Price, Quote & News

Company Profile

Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase II clinical trial...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 577 3600

Website: www.vistagen.com

Address:

343 Allerton Avenue, South San Francisco, United States

JSP_Dilution_Player Feb. 3 at 8:39 PM

added few more today. catalysts/cash plays $TOVX $FATE $TCRX $VTGN $AZTR

0 · Reply

explover Feb. 3 at 8:32 PM

$VTGN seems kinda inevitable for them to stop PALISADE-4. To get the drug approved they'll have to show something like p-val<0.0001, which is not happening ever judging from the pooled PALISADE-1-3 data, but they know that already. Having Orbimed and Nantahala as shareholders is good, they are unlikely to let the management waste cash, announcement on strategic alternatives is very likely after the release of Nasdaq deficiency notice and Feb 12-14 quarterly report. Very nice undervalued shell priced for the management to continue beating a dead horse.

0 · Reply

mark31 Feb. 3 at 8:14 PM

$VTGN

0 · Reply

ACInvestorBlog Feb. 3 at 7:51 PM

$VTGN trading at 54c with a net cash per share of $1.32

0 · Reply

nightstocker15 Feb. 3 at 7:12 PM

$VTGN this is where you buy not sell

2 · Reply

seppi Feb. 3 at 6:35 PM

$VTGN bye bye vtgn

0 · Reply

Haimalon Feb. 3 at 6:16 PM

$VTGN No floor here , you keep averaging dawn , dawn and dawn …

0 · Reply

Cello69 Feb. 3 at 5:32 PM

$VTGN added 5000

0 · Reply

watchaddict Feb. 3 at 5:25 PM

$VTGN Co0o0oo00o0o0o0o0o00ked

0 · Reply

Haimalon Feb. 3 at 3:50 PM

$VTGN More than six weeks from the big drop and no Singh , this guy must get fired and forced to give back all bonuses received over the years …

1 · Reply

INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vistagen Therapeutics

Jan 28, 2026, 2:44 PM EST - 6 days ago

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vistagen Therapeutics

Jan 22, 2026, 10:45 AM EST - 12 days ago

VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) DEADLINE ALERT – Bernstein Liebhard LLP Reminds Vistagen Therapeutics, Inc. Investors of Upcoming Deadline

Jan 16, 2026, 5:06 PM EST - 18 days ago

VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) INVESTOR ALERT Investors With Large Losses in Vistagen Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Dec 17, 2025, 12:42 PM EST - 6 weeks ago

Vistagen's Social Anxiety Disorder Drug Disappoints In Pivotal Late-Stage Study

Dec 17, 2025, 8:30 AM EST - 6 weeks ago

Vistagen Announces Topline Results from PALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Dec 1, 2025, 8:30 AM EST - 2 months ago

Vistagen Appoints Nick Tressler as Chief Financial Officer

Nov 26, 2025, 8:30 AM EST - 2 months ago

Vistagen Reports Findings on PH80's Brain and Autonomic Effects in Women with Menopausal Hot Flashes at The Menopause Society 2025 Annual Meeting

Nov 18, 2025, 7:45 AM EST - 2 months ago

Vistagen Therapeutics: Intranasal Pherines And A Make-Or-Break 2026

Nov 13, 2025, 7:01 PM EST - 2 months ago

Vistagen Therapeutics, Inc. (VTGN) Q2 2026 Earnings Call Transcript

Nov 13, 2025, 4:30 PM EST - 2 months ago

Vistagen Reports Fiscal Year 2026 Second Quarter Financial Results and Provides Corporate Update

Nov 10, 2025, 8:30 AM EST - 3 months ago

Vistagen to Report Fiscal Year 2026 Second Quarter Results and Host Corporate Update Conference Call on November 13, 2025

Nov 5, 2025, 8:30 AM EST - 3 months ago

Vistagen to Participate in Stifel Healthcare Conference 2025

Nov 3, 2025, 8:30 AM EST - 3 months ago

Vistagen Completes PALISADE-3 Phase 3 Public Speaking Challenge Study for the Acute Treatment of Social Anxiety Disorder

Oct 29, 2025, 8:30 AM EDT - 3 months ago

Vistagen Appoints Paul Edick to its Board of Directors

Oct 16, 2025, 8:30 AM EDT - 3 months ago

Vistagen to Present at The Menopause Society 2025 Annual Meeting

Sep 9, 2025, 8:30 AM EDT - 5 months ago

Vistagen to Present at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Aug 8, 2025, 2:13 PM EDT - 6 months ago

Vistagen Therapeutics, Inc. (VTGN) Q1 2026 Earnings Call Transcript

Aug 7, 2025, 4:30 PM EDT - 6 months ago

Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update

Jul 31, 2025, 8:30 AM EDT - 6 months ago

Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025

Jul 24, 2025, 8:30 AM EDT - 6 months ago

Vistagen to Present at the BTIG Virtual Biotechnology Conference

Jul 15, 2025, 8:30 AM EDT - 7 months ago

Vistagen Honored for Outstanding Workplace Culture and Mental Health Leadership

Jun 25, 2025, 8:30 AM EDT - 7 months ago

Vistagen Appoints Elissa Cote as Chief Corporate Development Officer

Jun 17, 2025, 6:49 PM EDT - 8 months ago

Vistagen Therapeutics, Inc. (VTGN) Q4 2025 Earnings Call Transcript

Jun 17, 2025, 4:30 PM EDT - 8 months ago

Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

Jun 12, 2025, 8:30 AM EDT - 8 months ago

Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025

Jun 2, 2025, 8:30 AM EDT - 8 months ago

Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year

May 28, 2025, 8:30 AM EDT - 8 months ago

Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York

May 23, 2025, 8:30 AM EDT - 9 months ago

Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference

Apr 17, 2025, 8:30 AM EDT - 10 months ago

Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference

Mar 19, 2025, 8:30 AM EDT - 11 months ago

Vistagen to Present at the 2025 Anxiety and Depression Association Conference

Mar 4, 2025, 8:30 AM EST - 1 year ago

Vistagen to Participate in Stifel 2025 Virtual CNS Forum

Feb 20, 2025, 8:30 AM EST - 1 year ago

Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference

Feb 14, 2025, 6:19 PM EST - 1 year ago

Vistagen: Pherine Candidate Proof Of Concept Continues With Fifth Indication

Feb 13, 2025, 8:47 PM EST - 1 year ago

Vistagen Therapeutics, Inc. (VTGN) Q3 2025 Earnings Call Transcript

Feb 13, 2025, 4:30 PM EST - 1 year ago

Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update

Feb 6, 2025, 8:30 AM EST - 1 year ago

Vistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025

Feb 5, 2025, 8:30 AM EST - 1 year ago

Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain

Jan 14, 2025, 8:30 AM EST - 1 year ago

Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia

Jan 10, 2025, 8:30 AM EST - 1 year ago

Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder

Nov 14, 2024, 8:30 AM EST - 1 year ago

Vistagen to Present at the Stifel 2024 Healthcare Conference

Nov 10, 2024, 7:43 AM EST - 1 year ago

Vistagen Therapeutics, Inc. (VTGN) Q2 2025 Earnings Call Transcript

Nov 7, 2024, 4:20 PM EST - 1 year ago

Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update

Nov 5, 2024, 8:30 AM EST - 1 year ago

Vistagen to Present at the 2024 Neuroscience Education Institute Congress

JSP_Dilution_Player Feb. 3 at 8:39 PM

added few more today. catalysts/cash plays $TOVX $FATE $TCRX $VTGN $AZTR

0 · Reply

explover Feb. 3 at 8:32 PM

0 · Reply

mark31 Feb. 3 at 8:14 PM

$VTGN

0 · Reply

ACInvestorBlog Feb. 3 at 7:51 PM

$VTGN trading at 54c with a net cash per share of $1.32

0 · Reply

nightstocker15 Feb. 3 at 7:12 PM

$VTGN this is where you buy not sell

2 · Reply

seppi Feb. 3 at 6:35 PM

$VTGN bye bye vtgn

0 · Reply

Haimalon Feb. 3 at 6:16 PM

$VTGN No floor here , you keep averaging dawn , dawn and dawn …

0 · Reply

Cello69 Feb. 3 at 5:32 PM

$VTGN added 5000

0 · Reply

watchaddict Feb. 3 at 5:25 PM

$VTGN Co0o0oo00o0o0o0o0o00ked

0 · Reply

Haimalon Feb. 3 at 3:50 PM

$VTGN More than six weeks from the big drop and no Singh , this guy must get fired and forced to give back all bonuses received over the years …

1 · Reply

Geo1313 Feb. 3 at 2:44 PM

$VTGN 🔥🚀

0 · Reply

mark31 Feb. 3 at 1:05 PM

$VTGN vanguard added in filing https://www.bamsec.com/filing/10290926000313?cik=1411685

0 · Reply

mark31 Feb. 3 at 1:01 PM

$VTGN vtgn starting to move

0 · Reply

AnalyticaInvestor Feb. 3 at 12:15 PM

$VTGN $EML $QMCO Good morning, investors. Liquidity and macro signals remain the main drivers as delayed labor data and mixed Fed commentary keep rate expectations fluid. On the watchlist, $QMCO remains deeply discounted after a sharp YTD selloff, with insider buying standing out. $VTGN faces headline risk but has upcoming clinical milestones, while $EML trades near its 52 week low with recent director purchases signaling confidence. Among movers, Mexican hospitality developers jumped +30%, while $TNYA and $CDXS moved higher on healthcare momentum. SPACs stayed under pressure, with several down as much as 26% on thinning liquidity. Bitcoin treasury strategy names saw heavy churn as traders reacted to dilution and balance sheet headlines. Read the full Analytica Alpha 👇 https://analyticainvestor.beehiiv.com/p/delayed-jobs-data-stalls-clarity

0 · Reply